| Cantonetti, Maria |
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
|
KRdvsRd, NCT04096066: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant |
|
|
| Active, not recruiting | 3 | 84 | Europe | Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone | Fondazione EMN Italy Onlus | Multiple Myeloma, New Diagnosis Tumor | 01/26 | 01/26 | | |
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 07/28 | 07/30 | | |
| Recruiting | 2 | 160 | Europe | Nivolumab 10 MG/ML | Medical University of Gdansk, Medical Research Agency | Hodgkin Lymphoma | 09/22 | 07/26 | | |
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide |
|
|
| Terminated | 2 | 5 | Europe | Rituximab, Chemotherapy, Tenofovir alafenamide | Gruppo Italiano Malattie EMatologiche dell'Adulto | Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia | 05/24 | 05/24 | | |
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 520 | Europe | Quality of life questionnaires | Gruppo Italiano Malattie EMatologiche dell'Adulto | Multiple Myeloma | 12/24 | 12/24 | | |
| Not yet recruiting | N/A | 400 | Europe | | Fondazione Italiana Linfomi - ETS, Takeda | Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome | 07/26 | 07/26 | | |
| VENDITTI, Adriano |
| Recruiting | 3 | 172 | Europe | Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD | Gruppo Italiano Malattie EMatologiche dell'Adulto, MYNERVA (MYeloid Neoplasms Research Venture AIRC) programma speciale finanziato dall'AIRC - Associazione Italiana per la, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus | Acute Myeloid Leukemia With FLT3/ITD Mutation | 12/22 | 08/25 | | |
| Recruiting | 3 | 414 | Europe | Gemtuzumab Ozogamicin | Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L. | Acute Myeloid Leukemia | 04/25 | 04/27 | | |
| Recruiting | 3 | 322 | Europe, Canada, US | Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF | Arog Pharmaceuticals, Inc. | Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | 10/24 | 10/24 | | |
| Not yet recruiting | 3 | 339 | Europe, RoW | High intensity therapies, Low intensity therapies | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European Leukemia Net, Fundacion Para La Investigacion Hospital La Fe, Ostdeutsche Studiengruppe Haematologie Und Onkologie e.V., Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, TIMELEX | Acute Myeloid Leukemia, Relapse/Recurrence | 01/28 | 01/28 | | |
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML |
|
|
| Recruiting | 2 | 98 | Europe | RVU120, SEL120, Venetoclax | Ryvu Therapeutics SA | Acute Myeloid Leukemia | 02/26 | 09/26 | | |
| Recruiting | 2 | 94 | Europe, Canada | RVU120, SEL120 | Ryvu Therapeutics SA | Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | 02/26 | 09/26 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 |
|
|
| Recruiting | N/A | 104 | Europe | Venetoclax plus HMA | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia | 12/22 | 12/23 | | |
| Recruiting | N/A | 4000 | Europe | Registration into the STREAM platform | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 07/32 | 07/32 | | |
| Voso, Maria T |
| Recruiting | 3 | 274 | Europe | Azacitidine, AZA, Standard Chemotherapy, STD CHT, Allogeneic stem cell transplantation, HSCT | Gruppo Italiano Malattie EMatologiche dell'Adulto, AIFA - Italian Medicines Agency, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus | High-risk MDS | 03/24 | 03/24 | | |
| Recruiting | 2 | 22 | Europe | Luspatercept Injection [Reblozyl] | Associazione Qol-one, Celgene BMS | Myelodysplastic Syndromes, Del(5Q), Anemia, Transfusion-dependent Anemia | 12/24 | 12/29 | | |
| Completed | N/A | 215 | Europe | Luspatercept | Fondazione Italiana Sindromi Mielodisplastiche-ETS, Istituto Clinico Humanitas | Myeloid Dysplasia | 12/22 | 01/23 | | |
NCT04587856: Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients |
|
|
| Recruiting | N/A | 38 | Europe | bone marrow withdrawal | Gruppo Italiano Malattie EMatologiche dell'Adulto | Myelodysplastic Syndromes | 03/25 | 03/25 | | |
NCT03751917: Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia |
|
|
| Recruiting | N/A | 100 | Europe | Arsenic Trioxide, ATRA+ATO | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Promyelocytic Leukemia | 12/24 | 12/24 | | |
| Recruiting | N/A | 200 | Europe, Canada, US, RoW | | Immune Oncology Research Institute | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | 07/32 | 07/32 | | |
| Picardi, Alessandra |
| Recruiting | 3 | 274 | Europe | Azacitidine, AZA, Standard Chemotherapy, STD CHT, Allogeneic stem cell transplantation, HSCT | Gruppo Italiano Malattie EMatologiche dell'Adulto, AIFA - Italian Medicines Agency, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus | High-risk MDS | 03/24 | 03/24 | | |
| Active, not recruiting | 2 | 120 | Europe | Pentaglobin | Gruppo Italiano Trapianto di Midollo Osseo | Septic Shock | 05/24 | 05/25 | | |
| Maurillo, Luca |
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
| Recruiting | N/A | 343 | Europe, RoW | Questionnaire | Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC | Acute Myeloid Leukemia | 06/21 | 12/22 | | |
| Principe, Maria Ilaria Del |
| Recruiting | 2 | 32 | Europe | Ponatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Docteur-Yersin 12, 1110 Morges, Switzerland, FONDAZIONE GIMEMA | Chemotherapy, Leukemia, Acute Lymphoblastic | 02/25 | 07/28 | | |
NCT06382922: Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy |
|
|
| Recruiting | N/A | 300 | Europe | | University of Rome Tor Vergata | Invasive Aspergillosis | 07/24 | 06/25 | | |
NCT05772000: Clinical Significance of Occult Central Nervous System Localization |
|
|
| Recruiting | N/A | 70 | Europe | cerebrospinal fluids exams | University of Rome Tor Vergata | Acute Lymphoblastic Leukemia | 09/23 | 09/24 | | |
NCT03318770: Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
|
|
| Recruiting | N/A | 60 | Europe | Dasatinib and blinatumomab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoblastic Leukemia | 05/24 | 05/24 | | |
| Active, not recruiting | N/A | 78 | Europe | Gilteritinib | University of Rome Tor Vergata | Acute Myeloid Leukemia | 05/24 | 12/24 | | |
| Franceschini, Luca |
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 520 | Europe | Quality of life questionnaires | Gruppo Italiano Malattie EMatologiche dell'Adulto | Multiple Myeloma | 12/24 | 12/24 | | |
| Principe, Del |
| No trials found |
